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SUMMARY
Aim: To evaluate the impact on the clinical service ofincorporating cardiac troponin T (cTnT)
measurement into the existing chest pain care pathway in our district general hospital.
Methods: We randomised 200 consecutive patients admitted with acute chest pain, but without
ST elevation on ECG, either to our existing chest pain care pathway (pathway 1) or to a new
pathway incorporating semi-quantitative cTnT measurement (pathway 2).
Results: In comparison with pathway 1, in pathway 2 there was a strong trend towards reduced
length of stay (3.13 v 4.36 days, p=0.08), and reduced usage of low molecular weight heparin
(LMWH) (4.59 v 5.45 doses per patient, p=0.05). The number ofcardiac events at three months
in care pathway 1 (14/92) and care pathway 2 (22/108) did not significantly differ, p=0.34. In
patients withatypical chestpain, there was a tendencyforcardiologists to discharge earlier (1.75
v 2.03 days, p=0.07) and use less LMWH (2.04 v 2.97 doses, p=0.06) than general physicians.
Conclusion: In this study, incorporation ofcTnT measurement into a chest pain care pathway
resulted in a strong trend towards reduced length of hospital stay and LMWH usage.
INTRODUCTION
Chestpainis oneofthecommonestpresentations
to the accident and emergency department. The
traditional riskfactors obtained from the clinical
history and abnormalities on the electro-
cardiogram (ECG) discriminate poorly between
cardiac and non-cardiac pain, resulting in some
4-8% of patients with an acute myocardial
infarction being discharged.' This may be
catastrophic for the individual, and it accounts
for 25% of litigation against emergency
departments in the US.2 For this reason, a large
proportion ofpatients presenting with chestpain
are admitted, although fewer than half of these
have an acute coronary syndrome.3 As chestpain
accounts for 20-30% of acute medical
admissions,3 patients at low-risk of a cardiac
event constitute about 10% of all hospital
admissions.
Measurement of cardiac troponins may aid risk
stratification and triage of this large group of
patients. Several studieshaveshownthatelevated
troponin levels are associated withincreasedrisk
ofsubsequentcardiac events.47 Howevermostof
these studies have been carried out in high-risk
populations in clinical trials, or in cardiology
units. The true value of a troponin assay in the
assessment of unselected patients in a district
general hospital is less certain.
In our hospital, as in many district general
hospitals, initial management of chest pain has
beenperformedbygeneralphysicians,withhigher
risk patients subsequently being referred to a
cardiologist. In order to standardise care, a care
pathway for patients admitted with chest pain
without ST-elevation on the ECG was in
operation. Patients were risk stratified on the
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basis of history, conventional risk factors for
coronary disease and presence of ischaemic
changes on the ECG. In an effort to improve the
efficiency ofthe service, we devised a new care
pathway incorporating serum cardiac troponin
T (cTnT) measurement into the risk assessment
algorithm. The care pathways represented
alternative accepted management strategies for
acutechestpain. Thepurposeofthis study was to
comparetheclinicaleffectivenessofthepathways
inanunselectedpopulationpresentingtoadistrict
hospital. Specifically we sought to address the
question ofwhether inclusion ofcTnT in the risk
stratification algorithm would influence length
of hospital stay or use of low molecular weight
heparin (LMWH).
SUBJECTS AND METHODS
Patient selection
Thestudypopulationconsistedof200consecutive
patients admitted with chest pain to the Mater
Hospital between May 22nd and October 12th
2000.The study was designed to be as inclusive
as possible; however, patients with a history of
myocardial infarction (MI) in the previous two
weeks, ST elevation on the admission ECG,
pleuritic chest pain, co-morbidity reducing life
expectancy (e.g. advancedmalignancy) andthose
unabletogiveanadequatehistory wereexcluded.
Studyprotocol
This was a prospective, randomised open
comparison oftwo care pathways. Patients were
randomisedtoPathway 1 orPathway 2according
to their accident and emergency number: odd
numbers were allocated to pathway 1 and even
numbers to pathway 2. Page 1 of both care
pathways was filled inby the admitting doctor. It
directed them to record clinical data, to take
appropriate bloodtests, andto assess theneedfor
cardiac monitoring. In Pathway 2 they were
directed to take two samples for point-of-care
serum cTnT measurement: the first at least six
hours after the onset of the most severe chest
pain, and the second at 12 hours. If the patient
presented more than 12 hours after the onset of
pain, or ifthe first sample was positive, a single
sample sufficed.
Thefirst seniordoctorassessing thepatientmade
the clinical risk assessment. This may have been
theregistrarontheweekdayeveningward-round,
or the consultant on the ward round on the
following morning. InPathway 1, the assessment
was made according to the character ofthe chest
pain, presence ofrisk factors for ischaemic heart
disease (IHD), and ECG characteristics. In
Pathway2,theassessmentwasbasedoncharacter
of chest pain, ECG characteristics, and serum
cTnTlevels. Those deemedtobe atlowriskwere
discharged early for outpatient exercise stress
testing (EST) if appropriate, whereas those
deemedtobeathigherriskwerekeptasinpatients
forintensive anti-anginal treatmentandEST (see
Fig. 1).
Risk factors for IHD were defined as:
hypercholesterolaemia: total serum cholesterol
>5.2mmol/1 or on statin therapy; hypertension:
units mmHg on three occasions or on anti-
hypertensive therapy; and diabetes mellitus:
fasting blood sugar >7.Ommol/1 or on diabetic
diet or medication. The patients were designated
as current, ex- ornon-smokers, accordingtotheir
response atthetime ofadmission. Family history
of IHD was also obtained from the patient at the
time of admission.
Datarelatingtoin-patientepisodeswereobtained
from the clinical notes. Follow-up data was
obtained by a research nurse using a standard
questionnaire administered by telephone three
months post-discharge, and from the patient's
GP orhospital records where necessary. Primary
end-points were the number of doses of LMWH
used and the length of hospital stay. Cardiac
events during the follow-up period were a
secondary end-point and included death from
IHD, readmission with MI or unstable angina,
andneedforrevascularisation. Inordertocompare
ourresults withprevious studies, MI was defined
as the combination of typical chest pain with
elevationincreatinekinasegreaterthantwicethe
upper limit of normal, with or without dynamic
ECG changes. Unstable angina was defined as a
typical history compatible with type IIIB of the
Braunwald classification.8
Analytical techniques
A semi-quantitative measurement of troponin T
was made using the Cardiac Reader (Roche
Diagnostics). 150p1 ofheparinised whole blood
was applied to the reader, and a result was
available after 12 minutes. A numerical value for
cTnT was obtained in the range 0.1-2.0,ug/l.
Elevations of cTnT either less than 0.1lug/l or
greaterthan2.0[tg/l gavereadingsLOW orHIGH
respectively. IfcTnT was notdetected, anegative
readingwasobtained.Althoughthemanufacturers
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History typical of
ischaemia?
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ECG or ECG or
cTnT cTnT
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Fig 1. Algorithm for the management of chest pain in Care Pathway 2.
(EST - Exercise Stress Test)
cut-off value for a positive result was >0.1Rg/l,
for this study we designated the test as being
positive ifany troponin T was detected. This is in
light ofstudies showing that troponin T levels in
the range 0.06-0.1 tg/l are associated with
increasedriskofcardiac events,5 andisconsistent
with arecent paperthatrecommended areduction
in the cut-off value to 0.05[ig/l.9 Quality control
was assured by testing one kit in each batch of 10
againststandards. Allhouseofficers weretrained
toperformthe analysis. There are several cardiac
Troponin I assays, -each with their individual
characteristics, available on the market but only
one cTnT assay is available. The cTnT assay was
chosen so that the current results could be more
easily compared with those from previous trials.
Statistical analysis
Allresults forcontinuous variables areexpressed
as means. The student's t-test and the Mann-
Whitney test were used to compare continuous
variables between groups when the distributions
were normal and non-parametric respectively.
TheX2-testwiththeappropriatenumberofdegrees
of freedom was used to compare categorical
variables. Analyses were performed on SPSS
(version 10.1) software package. Recruitment of
200 patients was sufficient to have 80% power to
detect a difference of 1.5 days in length of stay
betweenthe groups atthe5% levelofsignificance.
RESULTS
Of the 200 patients enrolled, 92 (46%) were
randomised to pathway 1, and 108 (54%) to
pathway 2. Baseline characteristics were similar
in both groups (Table).
14 patients (7.0%) were diagnosed with
myocardial infarction based on elevation of
cardiac enzymes within the first 24 hours of
admission. Unstable angina was diagnosed in 97
patients (48.5%), and the remaining 89 patients
(44.5%) were considered to have non-cardiac
chest pain.
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TABLE
Patient characteristics at baseline
Characteristic All Patients Care pathway 1 Care pathway 2 p-value
number % number % number %
Mean Age (years) 62.3 63.4 61.4 0.28
Male 106(53) 46(50) 60(56) 0.43
Smoking Status
Current 54(27) 24(26) 30(28) 0.57
Ex-smoker 21(11) 14(15) 7(6)
Hypertension 78(39) 39(42) 39(36) 0.36
Diabetes mellitus 23(12) 13(14) 10(9) 0.28
Hypercholesterolaemia 118(59) 53(58) 65(60) 0.71
Family history IHD 144(72) 67(73) 77(71) 0.75
Mean no. ofrisk factors 2.45 2.55 2.36 0.22
Personal history IHD 101(51) 49(53) 52(48) 0.47
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Fig 2. Mean number of doses ofLow Molecular Weight Heparin (A) and duration ofhospital stay (B) in care pathway
1 compared to care pathway 2.
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Troponin Tmeasurements
Of the 108 patients allocated to pathway 2, 106
hadserumcTnTtestingcompletedasperprotocol.
cTnT was positive in 15 (14%), including all five
patients with myocardial infarction, and 10 of48
(21%) withunstable angina. Eachpatientwith an
elevated cTnT was subsequently diagnosed as
having either amyocardial infarction orunstable
angina. Hence, although the sensitivity of cTnT
for acute coronary syndromes was low at 28%, it
was highly specific (100%).
Three patients who had normal cTnT on initial
sampling subsequently developedelevatedcTnT
on repeat sampling. Of the 15 patients with
elevated cTnT levels, five had no rise in creatine
kinase, fourhad no dynamic ECG changes, and a
further four had neither a rise in enzymes nor
ECG changes, and hence would not have been
identified as being at high risk by traditional
markers.
Comparison ofcare pathways and teams
In comparison with pathway 1, in pathway 2
there was a strong trend for a reduction in use of
LMWH (p=0.05) and in mean length of stay
(p=0.08) (Fig. 2). In the 89 patients diagnosed as
havingnon-cardiac chestpain, there was a strong
trend for reduced use of LMWH (2.04 v 2.97
doses, p=0.06) andreducedinpatient stay (1.75 v
2.03 days, p=0.07) in patients assessed by the
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cardiology team compared with those assessed
by general physicians. This trend in the triage of
non-cardiac chest pain was particularly evident
when cTnT measurements were employed (see
Fig. 3).
Follow-up
Cardiac events occurred in 36 patients (18%) in
the 3-month follow-up period. 22 of the 106
(21%)patientswhohadcTnTtestedhadacardiac
event, including 5 of 15 patients (33%) whowere
cTnTpositiveand 17 of91 (19%) ofthosetesting
negative. The excess rate of events in patients
testing positive for cTnT failed to reach
significance (p=O. 19). Thepositive andnegative
predictivevaluesofanelevatedcTnTforacardiac
event occurring within 3 months were 33% and
81% respectively.
Inthe3-monthfollow-up, 14of92patients (15%)
on pathway 1 had an event, compared with 22 of
108 (20%) patients on pathway 2. There was no
significant difference in the frequency ofevents
between the two pathways (p=0.34).
DISCUSSION
The principal aim ofthis study was to determine
whether incorporation of serum cTnT
measurementintotheriskstratificationalgorithm
of our existing chest pain care pathway could
improve the efficiency ofthe service. We found
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Fig 3. Mean number ofdoses of Low Molecular Weight Heparin (A) and duration ofhospital stay (B) in patients with
non-cardiac chestpain assessedby acardiologist (n=24)compared to those assessedby aphysician (n=65). There
was a trend towards a greater reduction in these parameters when assessment was made by a cardiologist using
pathway 2.
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that there was a strong trend, whichjust failed to
reach statistical significance, towards reduced
lengthofhospital stayandusageofLMWHwhen
cTnT measurement was employed.
This has major resource implications for a busy
district general hospital. Assuming thepattern of
admissions throughout the year was similar to
that seen in the current study, over 500 patients
withchestpainwouldbeadmittedtoourhospital.
As patients randomised to Care Pathway 2 spent
on average 1.23 less nights in hospital, over 600
bed nights would be made available for other
patients.
Most previous studies of serum troponin
measurements in the assessment of chest pain
have been carried out in high risk populations5-7
orincardiology units.10"'I Ourstudy hadminimal
exclusion criteria and therefore more accurately
reflects thecharacteristics ofpatients admittedto
adistrictgeneralhospitalwithchestpain. Elderly
patients were included (age range 28-94 years),
aswerethosewithsignificantco-morbidity(other
than dementia and advanced malignancy). The
differencebetweenourstudypopulationandthose
of previous trials which required dynamic ECG
changes for inclusion, is illustrated by a cardiac
event rate of 18% at 3-month follow-up in our
study, comparedwith72% and52% eventratesat
30 days in the GUSTO-Ila and TRIM studies.6'7
The impact of cTnT measurement in these high
risk populations cannot be extrapolated directly
to the district general hospital setting. In our
study, due to the presence of significant co-
morbidity, many patients stayed longer than was
required to manage solely their chest pain. This
mayhavedilutedthebenefitofcTnTmeasurement
in improving efficiency, but would give a more
accurate assessment of the true impact of cTnT
measurement in a district general hospital.
Furthermore, by excluding patients with
nondiagnostic ECG's, these studies excludedthe
majorityofpatientspresentingtoadistrictgeneral
hospitalwithchestpain,includingthoseproviding
the greatest diagnostic challenge.
Hammfoundthat 1.1Y% ofpatientswhopresented
to the emergency department with chestpain and
who testednegative forcTnThad acardiac death
or MI in the following 30 days.4 He concluded
that a negative result could therefore allow rapid
andsafedischargeofpatientsfromtheemergency
department. Our study raises some doubts as to
thevalidityofthisapproach.Firstly,threepatients,
including one patient with evolving infarction,
who tested negative for cTnT greater than six
hours after the onset of most severe chest pain
subsequently tested positive on repeat sampling
at 12 hours. This reflects the delay in release of
cTnT from damaged myocardial cells, and is in
keeping withotherstudies.7 Secondly, anegative
cTnT does not rule out the presence of an acute
coronary syndrome or the occurrence of
subsequent cardiac events. Only 21% ofpatients
diagnosed with unstable angina in our study had
raised cTnT levels, a proportion similar to that
seen inotherstudies.4'6 10 19% ofpatients testing
negative for cTnT had an event by three months,
including one cardiac death in apatient who also
had a negative EST pre-discharge. Furthermore,
in Hamm's study, all patients diagnosed with
unstable angina were admitted and treated with
LMWH, including those testing negative for
cTnT. The event rate may have been greater if
these patients had been discharged directly from
the emergency room.
Ourstudyshowedthatmembersofthecardiology
team tended to be more efficient than general
physiciansinmanagingpatientswithnon-cardiac
chestpain,particularlywhencTnTmeasurements
wereemployed(seeFig. 3).TheadditionofcTnT
measurementtothedecision-making processhad
little impact in reducing the LMWH usage or the
length ofstay forpatients with non-cardiac chest
pain assessed by a general physician. This
provides a strong argument for admitting all
patients with chest pain to a cardiac unit, where
they can be managed by a multi-disciplinary
chest pain team.
Therewas no significantdifference ineventrates
at 3 months in the patients testing positive for
cTnT compared with those testing negative, but
our study was not powered to detect this. The
prognostic value of cTnT measurement is,
however, illustrated by the fact that we detected
fourpatientswithelevatedcTnTlevelswhowould
not have been identified as being high risk by
ECG or cardiac enzymes. Of these, two had
cardiac events during follow-up.
The major limitation of the study is that it has
inadequate power to detect differences in length
of stay of less than 1.5 days between the two
groups. Therefore, although the improvement in
efficiency with cTnT measurement fails to reach
significance in the study, we feel that if we were
to ignore the strong trend towards improved
C The Ulster Medical Society, 2003.
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efficiency, we would be committing a type two
error, and be discounting a smaller but still
clinically important effect. We had anticipated
that the impact ofcTnT would have been greater
than that seen. A recent randomised trial of
patients admitted to a coronary care unit showed
a 66% reduction in length of stay when a cTnI-
basedalgorithmwascomparedwithstandardrisk
stratification."I Howeverthis trial didnotinclude
the time spent on the general wards following
discharge from the coronary care unit, which as
seen in our study, dilutes the impact of troponin
measurement on overall length ofstay, but more
accurately reflects the overall expenditure.
In conclusion, our study supports the hypothesis
that incorporating serum troponin measurement
into a risk stratification care pathway improves
service efficiency and is safe. This is likely to be
mostefficient inthe setting ofachestpainunitor
cardiac unit, wherepatients are assessedbythose
most experienced in the management of acute
coronary syndromes.
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